Chitosan oligosaccharides: A potential therapeutic agent for inhibiting foam cell formation in atherosclerosis
Foam cell formation is a key hallmark in atherosclerosis and associated cardiovascular diseases (CVDs). The potential anti-atherosclerotic potential of chitosan oligosaccharides (COS) was investigated using oxLDL-treated RAW264.7 murine cells. COS treatment led to a significant inhibition of lipid a...
Gespeichert in:
| Veröffentlicht in: | International journal of biological macromolecules 2024-12, Vol.282 (Pt 4), p.137186, Article 137186 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Pt 4 |
| container_start_page | 137186 |
| container_title | International journal of biological macromolecules |
| container_volume | 282 |
| creator | Le, My Phuong Thi Marasinghe, Chathuri Kaushalya Je, Jae-Young |
| description | Foam cell formation is a key hallmark in atherosclerosis and associated cardiovascular diseases (CVDs). The potential anti-atherosclerotic potential of chitosan oligosaccharides (COS) was investigated using oxLDL-treated RAW264.7 murine cells. COS treatment led to a significant inhibition of lipid accumulation, as demonstrated by Oil Red O staining, and reduced levels of total cholesterol, free cholesterol, cholesterol esters, and triglycerides in.oxLDL-treated RAW264.7 cells. COS blocked cholesterol influx through down-regulating class A1 scavenger receptors (SR-A1) and cluster of differentiation 36 (CD36) expression and stimulated cholesterol efflux through up-regulating ABC transporters ABCA-1 and ABCG-1 expressions. Additionally, COS treatment stimulated nuclear signaling pathways involving peroxisome proliferator-activated receptor-γ (PPAR-γ) and liver X receptor α (LXR-α), and also led to the phosphorylation of AMP-activated protein kinase (AMPK). COS further demonstrated anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in oxLDL-treated RAW264.7 cells, through suppression of NF-κB signaling. Furthermore, COS alleviated oxidative stress induced by oxLDL by activating Nrf2 signaling and enhancing the expression of antioxidant genes, including heme oxygenase-1 (HO-1), superoxide dismutase (SOD), glutathione peroxidase (Gpx), and catalase (CAT). In conclusion, COS can be beneficial in preventing atherosclerosis and related diseases. |
| doi_str_mv | 10.1016/j.ijbiomac.2024.137186 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3123806290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0141813024079959</els_id><sourcerecordid>3123806290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c245t-bdfdac859f9f7d141e0fe8cf9b3f53e4ddff181bf1b4ade1f6b288a3b24bb3ea3</originalsourceid><addsrcrecordid>eNqFkE1vEzEQhi1ERUPhL1Q-ctngWW82Xk5UUVuQKnGBs-WPcTLR7jrYDhL_vl6l5crFHzPvOx8PY7cg1iCg_3xc09FSnIxbt6Lt1iC3oPo3bAVqOzRCCPmWrQR00CiQ4pq9z_lYo_0G1Dt2LYdugH6QKzbvDlRiNjOPI-3rw7mDSeQxf-F3_BQLzoXMyMsBkznhuZDjZl-DPMTEaT6QpULzvn7NxB2O45KYTKE41zQ3izFmNy4n5Q_sKpgx48eX-4b9erj_ufvWPP14_L67e2pc221KY33wxqnNEIaw9XULFAGVC4OVYSOx8z4EUGAD2M54hNDbVikjbdtZK9HIG_bpUveU4u8z5qInyst0ZsZ4zlpCK5Xo20FUaX-RujphThj0KdFk0l8NQi-s9VG_stYLa31hXY23Lz3OdkL_z_YKtwq-XgRYN_1DmHR2hLNDTwld0T7S_3o8A1V1l2o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3123806290</pqid></control><display><type>article</type><title>Chitosan oligosaccharides: A potential therapeutic agent for inhibiting foam cell formation in atherosclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Le, My Phuong Thi ; Marasinghe, Chathuri Kaushalya ; Je, Jae-Young</creator><creatorcontrib>Le, My Phuong Thi ; Marasinghe, Chathuri Kaushalya ; Je, Jae-Young</creatorcontrib><description>Foam cell formation is a key hallmark in atherosclerosis and associated cardiovascular diseases (CVDs). The potential anti-atherosclerotic potential of chitosan oligosaccharides (COS) was investigated using oxLDL-treated RAW264.7 murine cells. COS treatment led to a significant inhibition of lipid accumulation, as demonstrated by Oil Red O staining, and reduced levels of total cholesterol, free cholesterol, cholesterol esters, and triglycerides in.oxLDL-treated RAW264.7 cells. COS blocked cholesterol influx through down-regulating class A1 scavenger receptors (SR-A1) and cluster of differentiation 36 (CD36) expression and stimulated cholesterol efflux through up-regulating ABC transporters ABCA-1 and ABCG-1 expressions. Additionally, COS treatment stimulated nuclear signaling pathways involving peroxisome proliferator-activated receptor-γ (PPAR-γ) and liver X receptor α (LXR-α), and also led to the phosphorylation of AMP-activated protein kinase (AMPK). COS further demonstrated anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in oxLDL-treated RAW264.7 cells, through suppression of NF-κB signaling. Furthermore, COS alleviated oxidative stress induced by oxLDL by activating Nrf2 signaling and enhancing the expression of antioxidant genes, including heme oxygenase-1 (HO-1), superoxide dismutase (SOD), glutathione peroxidase (Gpx), and catalase (CAT). In conclusion, COS can be beneficial in preventing atherosclerosis and related diseases.</description><identifier>ISSN: 0141-8130</identifier><identifier>ISSN: 1879-0003</identifier><identifier>EISSN: 1879-0003</identifier><identifier>DOI: 10.1016/j.ijbiomac.2024.137186</identifier><identifier>PMID: 39491693</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Anti-inflammation ; Antioxidant ; Atherosclerosis ; Atherosclerosis - drug therapy ; Atherosclerosis - metabolism ; Chitosan - chemistry ; Chitosan - pharmacology ; Chitosan oligosaccharides ; Cholesterol - metabolism ; Foam cells ; Foam Cells - drug effects ; Foam Cells - metabolism ; Lipid Metabolism - drug effects ; Lipoproteins, LDL - metabolism ; Liver X Receptors - metabolism ; Mice ; NF-E2-Related Factor 2 - metabolism ; NF-kappa B - metabolism ; Oligosaccharides - chemistry ; Oligosaccharides - pharmacology ; Oxidative Stress - drug effects ; Oxidized LDL ; PPAR gamma - metabolism ; RAW 264.7 Cells ; Signal Transduction - drug effects</subject><ispartof>International journal of biological macromolecules, 2024-12, Vol.282 (Pt 4), p.137186, Article 137186</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c245t-bdfdac859f9f7d141e0fe8cf9b3f53e4ddff181bf1b4ade1f6b288a3b24bb3ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijbiomac.2024.137186$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39491693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Le, My Phuong Thi</creatorcontrib><creatorcontrib>Marasinghe, Chathuri Kaushalya</creatorcontrib><creatorcontrib>Je, Jae-Young</creatorcontrib><title>Chitosan oligosaccharides: A potential therapeutic agent for inhibiting foam cell formation in atherosclerosis</title><title>International journal of biological macromolecules</title><addtitle>Int J Biol Macromol</addtitle><description>Foam cell formation is a key hallmark in atherosclerosis and associated cardiovascular diseases (CVDs). The potential anti-atherosclerotic potential of chitosan oligosaccharides (COS) was investigated using oxLDL-treated RAW264.7 murine cells. COS treatment led to a significant inhibition of lipid accumulation, as demonstrated by Oil Red O staining, and reduced levels of total cholesterol, free cholesterol, cholesterol esters, and triglycerides in.oxLDL-treated RAW264.7 cells. COS blocked cholesterol influx through down-regulating class A1 scavenger receptors (SR-A1) and cluster of differentiation 36 (CD36) expression and stimulated cholesterol efflux through up-regulating ABC transporters ABCA-1 and ABCG-1 expressions. Additionally, COS treatment stimulated nuclear signaling pathways involving peroxisome proliferator-activated receptor-γ (PPAR-γ) and liver X receptor α (LXR-α), and also led to the phosphorylation of AMP-activated protein kinase (AMPK). COS further demonstrated anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in oxLDL-treated RAW264.7 cells, through suppression of NF-κB signaling. Furthermore, COS alleviated oxidative stress induced by oxLDL by activating Nrf2 signaling and enhancing the expression of antioxidant genes, including heme oxygenase-1 (HO-1), superoxide dismutase (SOD), glutathione peroxidase (Gpx), and catalase (CAT). In conclusion, COS can be beneficial in preventing atherosclerosis and related diseases.</description><subject>Animals</subject><subject>Anti-inflammation</subject><subject>Antioxidant</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - drug therapy</subject><subject>Atherosclerosis - metabolism</subject><subject>Chitosan - chemistry</subject><subject>Chitosan - pharmacology</subject><subject>Chitosan oligosaccharides</subject><subject>Cholesterol - metabolism</subject><subject>Foam cells</subject><subject>Foam Cells - drug effects</subject><subject>Foam Cells - metabolism</subject><subject>Lipid Metabolism - drug effects</subject><subject>Lipoproteins, LDL - metabolism</subject><subject>Liver X Receptors - metabolism</subject><subject>Mice</subject><subject>NF-E2-Related Factor 2 - metabolism</subject><subject>NF-kappa B - metabolism</subject><subject>Oligosaccharides - chemistry</subject><subject>Oligosaccharides - pharmacology</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidized LDL</subject><subject>PPAR gamma - metabolism</subject><subject>RAW 264.7 Cells</subject><subject>Signal Transduction - drug effects</subject><issn>0141-8130</issn><issn>1879-0003</issn><issn>1879-0003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1vEzEQhi1ERUPhL1Q-ctngWW82Xk5UUVuQKnGBs-WPcTLR7jrYDhL_vl6l5crFHzPvOx8PY7cg1iCg_3xc09FSnIxbt6Lt1iC3oPo3bAVqOzRCCPmWrQR00CiQ4pq9z_lYo_0G1Dt2LYdugH6QKzbvDlRiNjOPI-3rw7mDSeQxf-F3_BQLzoXMyMsBkznhuZDjZl-DPMTEaT6QpULzvn7NxB2O45KYTKE41zQ3izFmNy4n5Q_sKpgx48eX-4b9erj_ufvWPP14_L67e2pc221KY33wxqnNEIaw9XULFAGVC4OVYSOx8z4EUGAD2M54hNDbVikjbdtZK9HIG_bpUveU4u8z5qInyst0ZsZ4zlpCK5Xo20FUaX-RujphThj0KdFk0l8NQi-s9VG_stYLa31hXY23Lz3OdkL_z_YKtwq-XgRYN_1DmHR2hLNDTwld0T7S_3o8A1V1l2o</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Le, My Phuong Thi</creator><creator>Marasinghe, Chathuri Kaushalya</creator><creator>Je, Jae-Young</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202412</creationdate><title>Chitosan oligosaccharides: A potential therapeutic agent for inhibiting foam cell formation in atherosclerosis</title><author>Le, My Phuong Thi ; Marasinghe, Chathuri Kaushalya ; Je, Jae-Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c245t-bdfdac859f9f7d141e0fe8cf9b3f53e4ddff181bf1b4ade1f6b288a3b24bb3ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Anti-inflammation</topic><topic>Antioxidant</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - drug therapy</topic><topic>Atherosclerosis - metabolism</topic><topic>Chitosan - chemistry</topic><topic>Chitosan - pharmacology</topic><topic>Chitosan oligosaccharides</topic><topic>Cholesterol - metabolism</topic><topic>Foam cells</topic><topic>Foam Cells - drug effects</topic><topic>Foam Cells - metabolism</topic><topic>Lipid Metabolism - drug effects</topic><topic>Lipoproteins, LDL - metabolism</topic><topic>Liver X Receptors - metabolism</topic><topic>Mice</topic><topic>NF-E2-Related Factor 2 - metabolism</topic><topic>NF-kappa B - metabolism</topic><topic>Oligosaccharides - chemistry</topic><topic>Oligosaccharides - pharmacology</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidized LDL</topic><topic>PPAR gamma - metabolism</topic><topic>RAW 264.7 Cells</topic><topic>Signal Transduction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Le, My Phuong Thi</creatorcontrib><creatorcontrib>Marasinghe, Chathuri Kaushalya</creatorcontrib><creatorcontrib>Je, Jae-Young</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of biological macromolecules</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Le, My Phuong Thi</au><au>Marasinghe, Chathuri Kaushalya</au><au>Je, Jae-Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chitosan oligosaccharides: A potential therapeutic agent for inhibiting foam cell formation in atherosclerosis</atitle><jtitle>International journal of biological macromolecules</jtitle><addtitle>Int J Biol Macromol</addtitle><date>2024-12</date><risdate>2024</risdate><volume>282</volume><issue>Pt 4</issue><spage>137186</spage><pages>137186-</pages><artnum>137186</artnum><issn>0141-8130</issn><issn>1879-0003</issn><eissn>1879-0003</eissn><abstract>Foam cell formation is a key hallmark in atherosclerosis and associated cardiovascular diseases (CVDs). The potential anti-atherosclerotic potential of chitosan oligosaccharides (COS) was investigated using oxLDL-treated RAW264.7 murine cells. COS treatment led to a significant inhibition of lipid accumulation, as demonstrated by Oil Red O staining, and reduced levels of total cholesterol, free cholesterol, cholesterol esters, and triglycerides in.oxLDL-treated RAW264.7 cells. COS blocked cholesterol influx through down-regulating class A1 scavenger receptors (SR-A1) and cluster of differentiation 36 (CD36) expression and stimulated cholesterol efflux through up-regulating ABC transporters ABCA-1 and ABCG-1 expressions. Additionally, COS treatment stimulated nuclear signaling pathways involving peroxisome proliferator-activated receptor-γ (PPAR-γ) and liver X receptor α (LXR-α), and also led to the phosphorylation of AMP-activated protein kinase (AMPK). COS further demonstrated anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in oxLDL-treated RAW264.7 cells, through suppression of NF-κB signaling. Furthermore, COS alleviated oxidative stress induced by oxLDL by activating Nrf2 signaling and enhancing the expression of antioxidant genes, including heme oxygenase-1 (HO-1), superoxide dismutase (SOD), glutathione peroxidase (Gpx), and catalase (CAT). In conclusion, COS can be beneficial in preventing atherosclerosis and related diseases.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39491693</pmid><doi>10.1016/j.ijbiomac.2024.137186</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0141-8130 |
| ispartof | International journal of biological macromolecules, 2024-12, Vol.282 (Pt 4), p.137186, Article 137186 |
| issn | 0141-8130 1879-0003 1879-0003 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3123806290 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Anti-inflammation Antioxidant Atherosclerosis Atherosclerosis - drug therapy Atherosclerosis - metabolism Chitosan - chemistry Chitosan - pharmacology Chitosan oligosaccharides Cholesterol - metabolism Foam cells Foam Cells - drug effects Foam Cells - metabolism Lipid Metabolism - drug effects Lipoproteins, LDL - metabolism Liver X Receptors - metabolism Mice NF-E2-Related Factor 2 - metabolism NF-kappa B - metabolism Oligosaccharides - chemistry Oligosaccharides - pharmacology Oxidative Stress - drug effects Oxidized LDL PPAR gamma - metabolism RAW 264.7 Cells Signal Transduction - drug effects |
| title | Chitosan oligosaccharides: A potential therapeutic agent for inhibiting foam cell formation in atherosclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A38%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chitosan%20oligosaccharides:%20A%20potential%20therapeutic%20agent%20for%20inhibiting%20foam%20cell%20formation%20in%20atherosclerosis&rft.jtitle=International%20journal%20of%20biological%20macromolecules&rft.au=Le,%20My%20Phuong%20Thi&rft.date=2024-12&rft.volume=282&rft.issue=Pt%204&rft.spage=137186&rft.pages=137186-&rft.artnum=137186&rft.issn=0141-8130&rft.eissn=1879-0003&rft_id=info:doi/10.1016/j.ijbiomac.2024.137186&rft_dat=%3Cproquest_cross%3E3123806290%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3123806290&rft_id=info:pmid/39491693&rft_els_id=S0141813024079959&rfr_iscdi=true |